AJOVY is available in an autoinjector. Learn more

You had searched for:

There were no results matching the query.

You can also browse the topics below to find what you are looking for.

Patient Profiles


Maura

Anna

Need help answering a question?

Support Services

  1. Download the Prescription and Service Request Form (PSRF)
  2. Fax the completed form to Shared Solutions® at 1-844-257-6127

Patients can call 1-800-887-8100, Monday–Friday, 8 am–6 pm CT.

More migraine-free days in patients with an inadequate response to 2 or more prior preventive treatments1*

FOCUS was the largest study of its kind (N=838) in patients with inadequate response to 2 or more classes of prior preventive treatments1

See study design

Significant reduction in average monthly migraine days compared to placebo after inadequate response to 2 or more classes of preventive treatments (primary endpoint)1

Change from baseline in average monthly mIgraine days during the focus phase 3b study1

Bar chart displaying primary endpoint data of the FOCUS study.

Patients who achieved ≥50% reduction in monthly average migraine days1

Percentage of patients achieving ≥50% reduction in average monthly migraine days vs placebo during the 12-week study period (secondary endpoint)1

Results in patients with an inadequate response to anticonvulsants or neurotoxins (exploratory analysis)#

3.8 mean reduction from baseline in monthly average migraine days for both quarterly and monthly arms vs 1.0 for placebo in patients with previous anticonvulsant use2

2.7 and 3.2 mean reduction from baseline in monthly average migraine days for quarterly and monthly arms, respectively, vs 0.2 for placebo in patients who previously used neurotoxins2

#For all exploratory analyses, no determination of statistical significance can be made and no conclusions should be drawn.

Patients experienced a significant reduction in the monthly average number of days using migraine-specific acute headache medication (secondary endpoint)2

Mean reduction of 3.7 days for quarterly dosing and 3.9 days for monthly dosing of migraine-specific acute headache medication use vs 0.6 days with placebo2

Suggestions to explore next

Continue to AJOVY Dosing page

Only 4 injection days per year with quarterly dosing

dosing for AJOVY
Continue to Half Life and antibody type page

AJOVY was studied in three phase 3 clinical trials and a long-term extension3

See STUDY designs